Newly Diagnosed Multiple Myeloma research hub
6 indexed studies · 3 currently recruiting
- authorisedTherapeutic confirmatory (Phase III)
A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).
This study tests a new treatment called CAR T-cell therapy for people newly diagnosed with multiple myeloma who cannot have an intensive stem cell transplant. Researchers want to see if a single dose of this personalised cell therapy keeps the cancer away longer than standard continuous medication.
Poland · Italy · Denmark - authorisedTherapeutic confirmatory (Phase III)
A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible (TE NDMM) (DURGA-6)
This study compares a new cell therapy called CAR-T with the standard stem cell transplant for people newly diagnosed with multiple myeloma. Researchers want to see if using a person's own modified immune cells keeps the cancer away longer than standard treatment and helps clear out cancer cells completely.
Germany · Spain · Norway - recruitingPHASE3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
This study compares two treatments for newly diagnosed multiple myeloma in people who can't have a stem cell transplant. It looks at whether one combination of medicines (BRd) works better than another (DRd) to control the cancer and reduce its signs.
United States · Argentina · Australia - not yet recruitingPhase III
A study of ramantamig plus daratumumab versus investigator’s choice in participants with newly diagnosed multiple myeloma
This study tests a new drug combination for adults recently diagnosed with multiple myeloma who cannot have a stem cell transplant. Researchers want to see if combining a new drug called ramantamig with daratumumab works better and is safer than standard NHS treatments.
United Kingdom · England · Scotland - recruitingPHASE3
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
This study is for people recently diagnosed with a type of blood cancer called multiple myeloma who can't have a stem cell transplant. It compares a new medicine called AZD0120 with current standard treatments to see if it works better at controlling the cancer and keeping people well for longer.
United States · Australia · Brazil - active not recruitingPHASE3
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
This study looks at a new drug combination, E-KRd, for people just diagnosed with multiple myeloma. It adds a drug called Elotuzumab to a standard treatment (KRd) to see if it works better at controlling the cancer and keeping it away for longer.
Austria · Germany